Search
Close this search box.
Search
Close this search box.

研究摘要

世德主要的研究摘要和出版物

Cytopeutics® 与当地和国际医疗机构、学术界和研究机构合作,在国际同行评审期刊和国际会议上发表了许多研究成果。

了解更多关于世德的消息:
Synergistic effects of intracoronary infusion of autologous bone marrow-derived mesenchymal stem cells and revascularization procedure on improvement of cardiac function in patients with sever ischemic cardiomyopathy.
Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll/lll randomized controlled trial.
Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy.
Improved cells survival and paracrine capacity of human embryonic stem cell-derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension.
Mesenchymal stromal cells (Cyto-MSC) are well-tolerated and associated with renal function improvement in patients with chronic kidney disease: An observation retrospective study.
BM-MSC accelerates acute stroke recovery in a randomized placebo- controlled clinical phase ll/lll study.
Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro.
Allogenic cord-derived MSC infusion is safe and improves metabolic functions of uncontrolled diabetes patients.
Allogenic Wharton’s jelly mesenchymal stromal cells intravenous infusion increase serum insulin like growth factor 1 and dehydroepiandrosterone in healthy volunteers.
Dose-dependent immunomodulatory effect of intravenous allogenic umbilical cord-derived mesenchymal stromal cells (Cytopeutics CLV-100) infusion in healthy volunteers.
Autologous bone marrow mesenchymal stromal cells can treat arthritic joints of rheumatoid arthritis patients: Reports of two patients.
Cytopeutics® umbilical cord mesenchymal stromal cells (CYTO-MSC) for patients with grade ll-lv acute graft-versus-host disease: A phase l/ll clinical study-protocol overview.
A safe and simple approach to obtaining sufficient cytokine induced killer (CIK) cells from criticallyill cancer patients without the need for apheresis or peripheral mobilization.
Arthroscopic evidence of cartilage regeneration in severe knee cartilage defects and osteoarthritis following treatment with allogenic umbilical cord-derived mesenchymal stromal cells (Chondrocell- Ex).
Intra articular injection of autologous bone-marrow-derived mesenchymal stromal cells in patients with moderate to severe osteoarthritis.
Umbilical cord-derived mesenchymal stem cell infusion improved liver function in liver cirrhosis and is associated with viral load reduction.
Autologous cultivated oral mucosal epithelial cells transplantation (COMET) with amniotic membrane-based sheets for severe ocular chemical injury.
Safety and efficacy of human Wharton’s jelly-derived mesenchymal stem cells therapy for retinal degeneration.
Combination BM-MSC with BM-MNC is better than BM-MNC alone in resolution of large ischemic ulcers: A phase ll/lll clinical randomized study.

研究在冠脉内输注自体骨髓间充质干细胞和血运重建术对改善重度缺血性心脏病患者心肌功能的协同作用。

自体间充质干细胞( MSC) 输注改善严重缺血性心脏病的心室射血分数与心壁厚度:综合临床中心第二期/三期的随机对照试验的结果。

研究经冷冻的骨髓间充质干细胞对治疗严重缺血性扩张型心肌病的安全性和疗效。

提高源自人类胚胎干细胞的间充质干细胞存活率和旁分泌能力以促进治疗潜在的肺动脉高血压。
慢性肾脏病患者对间充质干细胞 (CYTO-MSC) 有良好的耐受性及肾功能得到改善 – 前瞻性观察型研究。
BM-MSC加速急性中风的复原,第二期/三期安慰剂对照性随机化临床研究。
以从骨髓衍生的骨髓间充质干细胞体外培养神经元样细胞。
同源异体的MSC输注安全且可改善不受控糖尿病患者的代谢功能。
同种异体脐带胶质间充质干细胞 (WJ-MSC) 的静脉注射可增加健康志愿者的血清胰岛素样生长因子-1和脱氢表雄酮 (DHEA) 的水平。
健康志愿者接受异体脐带间充质细胞 (Cytopeutics CLV-100) 静脉注射后的剂量依存性免疫调节效果。
自体骨髓间充质干细胞可治疗类风湿性关节炎:2名患者为例。
适用于II-IV级急性移植物抗宿主病的Cytopeutics®脐带间充质干细胞(CYTO-MSC) – I/II期临床研究之试验方案概括。
无需血浆分离术或外周血干细胞驱动即可让危重癌症病患者获得足够的细胞因子激活型杀伤细胞 (CIK) 的安全简便方案。
关节镜图像证实异体间充质干细胞(Chondrocell-Ex)治疗可促进重度膝关节软骨损伤患者的软骨再生。
研究于关节内注射自体骨髓间充质干细胞可舒缓关节炎患者的病情。
注射脐带衍生的间充质干细胞可改善肝硬化的肝功能并与病毒负荷减少有关。
探讨于羊膜基地膜面上进行自体培养口腔黏膜上皮细胞移植 (COMET) 对重度眼部化学性灼伤的影响。
研究人类脐带胶质间充质干细胞治疗视网膜变性的安全性和有效性。
BM-MSC与BM-MNC的结合体比单一BM-MNC更有效地解决大型缺血性溃疡:第二期/三期随机临床研究。
This site is registered on wpml.org as a development site.